Fig. 8

The in vivo effect of YC-1 combined with PA + LC treatment on tumor xenografts. A Experimental schedule of HepG2 xenograft tumors in the four treatment groups, including control, YC-1, PA + LC, and YC-1 + PA + LC. B Western blot analysis of HIF-1α protein expression in control and YC-1-treated xenograft tumors. Four tumors were randomly selected from each treatment group. C Mean tumor volume of HepG2 xenografts from the four treatment groups. D Macroscopic appearance of tumors from the four treatment groups. E Western blot analysis of hexanoyl lysine (HEL) protein expression in HepG2 xenograft tumors from the four treatment groups. Three tumors were randomly selected from each treatment group. F Western blot analysis of cleaved caspase 3 protein expression in HepG2 xenograft tumors from the four treatment groups. Three tumors were randomly selected from each treatment group. G Body weight transition of mice during the treatment period. H Blood examination of serum free fatty acid (FFA) levels in mice from the four treatment groups. I Blood examination of serum triglyceride (TG) and glucose levels in mice from the four treatment groups. Values are presented as the mean ± standard error of the mean (SEM). N.S.: not significant, *P < 0.05, **P < 0.01 versus control